Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market
Zomedica (NYSE American:ZOM) has entered into a license and supply agreement with Cresilon Inc. for the Vetigel® hemostatic gel product line. The agreement grants Zomedica exclusive marketing and sales rights in the United States and non-exclusive rights internationally.
Vetigel is a plant-based formula designed to rapidly stop bleeding when applied directly to wounds. The product has been clinically validated for multiple applications, including surgical procedures, dental applications, emergency care, and liver biopsies. Key advantages include its ability to stop bleeding in seconds without becoming part of the clot.
Under the agreement, Zomedica will manage U.S. customer supply and collaborate with Cresilon for international customer support. The company plans to leverage its existing field sales team, trade show programs, and continuing education initiatives to expand Vetigel's market presence.
Zomedica (NYSE American:ZOM) ha stipulato un accordo di licenza e fornitura con Cresilon Inc. per la linea di prodotti in gel emostatico Vetigel®. L'accordo concede a Zomedica diritti di marketing e vendita esclusivi negli Stati Uniti e diritti non esclusivi a livello internazionale.
Vetigel è una formula a base vegetale progettata per fermare rapidamente il sanguinamento quando applicata direttamente sulle ferite. Il prodotto è stato validato clinicamente per molteplici applicazioni, tra cui procedure chirurgiche, applicazioni dentali, cure di emergenza e biopsie epatiche. I principali vantaggi includono la sua capacità di fermare il sanguinamento in pochi secondi senza diventare parte del coagulo.
In base all'accordo, Zomedica gestirà la fornitura ai clienti statunitensi e collaborerà con Cresilon per il supporto ai clienti internazionali. L'azienda prevede di utilizzare il proprio team di vendita sul campo, i programmi per fiere e le iniziative di educazione continua per ampliare la presenza di Vetigel nel mercato.
Zomedica (NYSE American:ZOM) ha llegado a un acuerdo de licencia y suministro con Cresilon Inc. para la línea de productos de gel hemostático Vetigel®. El acuerdo otorga a Zomedica derechos exclusivos de marketing y ventas en los Estados Unidos y derechos no exclusivos a nivel internacional.
Vetigel es una fórmula a base de plantas diseñada para detener rápidamente el sangrado cuando se aplica directamente sobre las heridas. El producto ha sido validado clínicamente para múltiples aplicaciones, incluyendo procedimientos quirúrgicos, aplicaciones dentales, atención de emergencia y biopsias de hígado. Las principales ventajas incluyen su capacidad para detener el sangrado en segundos sin convertirse en parte del coágulo.
Según el acuerdo, Zomedica gestionará el suministro a clientes estadounidenses y colaborará con Cresilon para el apoyo a clientes internacionales. La empresa planea aprovechar su equipo de ventas de campo existente, programas de ferias y iniciativas de educación continua para ampliar la presencia de Vetigel en el mercado.
조메디카 (NYSE American:ZOM)는 베티젤® 지혈 젤 제품군에 대해 크레실론(Cresilon Inc.)과 라이센스 및 공급 계약을 체결했습니다. 이 계약은 조메디카에 미국 내 독점적인 마케팅 및 판매 권리와 국제적으로 비독점적인 권리를 부여합니다.
베티젤은 상처에 직접 적용했을 때 출혈을 신속하게 멈추도록 설계된 식물 기반 포뮬러입니다. 이 제품은 외과적 절차, 치과용 응용, 응급 치료 및 간 생검을 포함한 여러 용도에 대해 임상적으로 검증되었습니다. 주요 장점은 응급 치료를 몇 초 만에 제공하며, 응괴의 일부가 되지 않는 것입니다.
계약에 따라 조메디카는 미국 고객 공급 관리를 담당하고, 국제 고객 지원을 위해 크레실론과 협력할 것입니다. 회사는 기존의 현장 판매 팀, 무역 쇼 프로그램 및 지속적인 교육 이니셔티브를 활용하여 베티젤의 시장 존재감을 확장할 계획입니다.
Zomedica (NYSE American:ZOM) a conclu un accord de licence et de fourniture avec Cresilon Inc. pour la gamme de produits de gel hémostatique Vetigel®. Cet accord accorde à Zomedica des droits exclusifs de marketing et de vente aux États-Unis ainsi que des droits non exclusifs à l'international.
Vetigel est une formule à base de plantes conçue pour arrêter rapidement le saignement lorsqu'elle est appliquée directement sur les blessures. Le produit a été validé cliniquement pour de multiples applications, y compris les interventions chirurgicales, les applications dentaires, les soins d'urgence et les biopsies du foie. Les principaux avantages comprennent sa capacité à arrêter le saignement en quelques secondes sans devenir partie du caillot.
En vertu de l'accord, Zomedica gérera l'approvisionnement des clients américains et collaborera avec Cresilon pour le soutien à la clientèle internationale. L'entreprise prévoit d'exploiter son équipe de vente sur le terrain, ses programmes de salons commerciaux et ses initiatives de formation continue pour étendre la présence de Vetigel sur le marché.
Zomedica (NYSE American:ZOM) hat eine Lizenz- und Liefervereinbarung mit Cresilon Inc. für die Vetigel®-Produktreihe zur Blutstillung abgeschlossen. Die Vereinbarung gewährt Zomedica exklusive Marketing- und Vertriebsrechte in den Vereinigten Staaten sowie nicht-exklusive Rechte international.
Vetigel ist eine pflanzenbasierte Formel, die darauf ausgelegt ist, Blutungen schnell zu stoppen, wenn sie direkt auf Wunden aufgetragen wird. Das Produkt wurde klinisch für mehrere Anwendungen, einschließlich chirurgischer Eingriffe, zahnmedizinischer Anwendungen, Notfallversorgung und Leberbiopsien, validiert. Zu den wichtigsten Vorteilen gehört die Fähigkeit, Blutungen innerhalb von Sekunden zu stoppen, ohne Teil des Gerinnsels zu werden.
Im Rahmen der Vereinbarung wird Zomedica die Versorgung der US-Kunden verwalten und mit Cresilon für die internationale Kundenbetreuung zusammenarbeiten. Das Unternehmen plant, sein bestehendes Außendienstteam, Programme für Messen und Fortbildungsinitiativen zu nutzen, um die Marktpräsenz von Vetigel auszubauen.
- Exclusive U.S. distribution rights for Vetigel, expanding product portfolio
- Access to clinically validated hemostatic technology
- Leverages existing sales infrastructure for new product distribution
- Potential revenue expansion through both U.S. and international markets
- None.
Insights
The Vetigel® licensing agreement represents a strategic expansion of Zomedica's product portfolio in the $1.4 billion global veterinary hemostasis market. Plant-based hemostatic agents are disrupting traditional methods, offering significant advantages in bleeding control efficiency and safety. The technology's ability to achieve hemostasis within seconds, without becoming part of the clot matrix, provides a clear clinical advantage over conventional alternatives.
The exclusive U.S. distribution rights position Zomedica to capture substantial market share in the largest veterinary market globally. The product's versatility across surgical, dental and emergency applications expands the total addressable market significantly. Clinical validation through white papers strengthens the product's credibility and should accelerate adoption among veterinary practices seeking evidence-based solutions.
This deal marks a pivotal business expansion leveraging Zomedica's existing sales infrastructure and distribution channels. The agreement structure - exclusive in the U.S. and non-exclusive internationally - provides an optimal balance of market opportunity and operational flexibility. The synergy with Zomedica's current product portfolio and sales team enables efficient market penetration with minimal additional overhead.
The partnership aligns with Zomedica's strategic focus on high-margin, innovative veterinary solutions that improve practice efficiency and patient outcomes. By integrating Vetigel® into their portfolio, Zomedica strengthens its position in the veterinary market while diversifying revenue streams beyond diagnostics. The recurring nature of hemostatic product sales could provide stable, predictable revenue growth to complement their existing business lines.
The veterinary hemostasis market is experiencing rapid growth driven by increasing pet ownership and advanced veterinary procedures. Vetigel's plant-based formulation addresses the growing demand for biocompatible, effective solutions in veterinary medicine. The product's demonstrated superiority in liver biopsies and other challenging procedures positions it as a premium offering in a market segment where efficacy commands premium pricing.
For investors, this agreement represents a significant catalyst for Zomedica. The combination of exclusive U.S. rights, an established sales force and a clinically validated product suggests strong potential for revenue growth. The timing aligns with increasing veterinary spending trends and growing preference for innovative medical solutions in animal healthcare.
License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology
ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States.
Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.
Vetigel is a groundbreaking, plant-based formula designed to stop bleeding rapidly when applied directly to the source. Unlike traditional methods, Vetigel halts bleeding in seconds without becoming incorporated into the clot. The product has been validated in clinical studies reported in white papers, demonstrating its ability to save time during surgical procedures and significantly reduce blood loss in patients. Key applications include:
Surgical Procedures: Effective in controlling bleeding during soft organ biopsies and excisions;
Dental Applications: Successfully used to manage bleeding in routine and advanced dental procedures;
Emergency Care: Proven efficacy in treating venous and arterial bleeds; and
Liver Biopsy: Demonstrated to stop bleeding faster than competitive hemostatic agents.
"We are excited to add Vetigel® to Zomedica's portfolio of innovative veterinary products," said Kevin Klass, Senior Vice President of Sales at Zomedica. "Vetigel's ability to rapidly stop bleeding across a variety of procedures makes it an invaluable tool for veterinarians, enabling them to enhance patient outcomes while improving surgical efficiency. This partnership with Cresilon allows us to bring cutting-edge solutions to veterinary professionals in the U.S. and beyond."
Greg Blair, Zomedica's Senior Vice President, Business Development & Strategic Planning, added, "This new venture with Cresilon is another way Zomedica stays true to our mission of enhancing the quality of care for pets, increasing pet parent satisfaction, and improving the workflow, cash flow, and profitability of veterinary practices. By bringing innovative solutions like Vetigel to market, we are empowering veterinarians to deliver better outcomes and experiences for their patients and clients."
"This partnership with Zomedica is ideal for the future of Vetigel," said Joe Landolina, CEO of Cresilon. "Zomedica's established reputation, robust field sales team, and commitment to veterinary excellence make them the perfect match for expanding the reach of this revolutionary product. Together, we look forward to making Vetigel an essential tool for veterinary practices worldwide."
Vetigel's versatility and proven efficacy make it a game-changer for veterinary practices, addressing critical needs in both routine and emergency settings. Zomedica looks forward to expanding access to this exciting technology to more customers leveraging our existing field sales team, frequent trade show programs, and weekly continuing education programs.
For more information about Vetigel hemostatic gel, please visit https://zomedica.com/vetigel.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
About Cresilon
Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's plant-based technology has revolutionized the current standard by stopping bleeding in seconds. The company's current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit www.cresilon.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to Cresilon's ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the Vetigel® hemostatic gel line; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What are the key applications of Vetigel in veterinary medicine according to ZOM's announcement?
What are the distribution rights ZOM secured for Vetigel through this agreement?
How does Vetigel's hemostatic technology work according to ZOM's announcement?
How will ZOM distribute Vetigel to the veterinary market?
